BetterLife Pharma Inc (NPAU) - Total Assets
Based on the latest financial reports, BetterLife Pharma Inc (NPAU) holds total assets worth €229.34K EUR (≈ $268.12K USD) as of July 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See BetterLife Pharma Inc (NPAU) net asset quality to measure how much of total assets are equity-financed.
BetterLife Pharma Inc - Total Assets Trend (2017–2025)
This chart illustrates how BetterLife Pharma Inc's total assets have evolved over time, based on quarterly financial data. Check NPAU cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
BetterLife Pharma Inc - Asset Composition Analysis
Current Asset Composition (January 2025)
BetterLife Pharma Inc's total assets of €229.34K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 3.6% |
| Accounts Receivable | €11.64K | 5.2% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how BetterLife Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NPAU market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BetterLife Pharma Inc's current assets represent 100.0% of total assets in 2025, an increase from 74.6% in 2017.
- Cash Position: Cash and equivalents constituted 3.6% of total assets in 2025, down from 84.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 5.2% of total assets.
BetterLife Pharma Inc Competitors by Total Assets
Key competitors of BetterLife Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
BetterLife Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.04 | 0.07 | 0.16 |
| Quick Ratio | 0.04 | 0.07 | 0.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-5.76 Million | €-5.81 Million | €-5.89 Million |
BetterLife Pharma Inc - Advanced Valuation Insights
This section examines the relationship between BetterLife Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.41 |
| Latest Market Cap to Assets Ratio | 24.09 |
| Asset Growth Rate (YoY) | -30.7% |
| Total Assets | €224.96K |
| Market Capitalization | $5.42 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values BetterLife Pharma Inc's assets at a significant premium (24.09x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: BetterLife Pharma Inc's assets decreased by 30.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BetterLife Pharma Inc (2017–2025)
The table below shows the annual total assets of BetterLife Pharma Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-01-31 | €224.96K ≈ $263.01K |
-30.73% |
| 2024-01-31 | €324.75K ≈ $379.66K |
+334.58% |
| 2023-01-31 | €74.73K ≈ $87.36K |
-93.57% |
| 2022-01-31 | €1.16 Million ≈ $1.36 Million |
-13.10% |
| 2021-01-31 | €1.34 Million ≈ $1.56 Million |
-83.80% |
| 2020-01-31 | €8.25 Million ≈ $9.65 Million |
-4.01% |
| 2019-01-31 | €8.60 Million ≈ $10.05 Million |
+1715.30% |
| 2018-01-31 | €473.52K ≈ $553.60K |
+172.39% |
| 2017-01-31 | €173.84K ≈ $203.24K |
-- |
About BetterLife Pharma Inc
BetterLife Pharma Inc., a biotechnology company, primarily focuses on developing compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight viral infections. The company's products pipeline includes BETR-001 for the t… Read more